Check Cap (NASDAQ:CHEK) issued its earnings results on Monday. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03, Fidelity Earnings reports.
Shares of CHEK opened at $3.84 on Wednesday. Check Cap has a 12-month low of $3.08 and a 12-month high of $19.78.
CHEK has been the topic of a number of recent research reports. HC Wainwright set a $14.00 target price on Check Cap and gave the stock a “buy” rating in a report on Wednesday, August 1st. Zacks Investment Research cut Check Cap from a “buy” rating to a “hold” rating in a report on Tuesday, July 24th.
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.